Decoding the Tricky Variant: A New Test for Creutzfeldt-Jakob Disease
"A breakthrough in diagnosing a rare form of Creutzfeldt-Jakob disease could help prevent future outbreaks and protect vulnerable populations."
Variant Creutzfeldt-Jakob disease (vCJD) is a rare and fatal brain disorder linked to the consumption of meat from cattle infected with bovine spongiform encephalopathy (BSE), commonly known as mad cow disease. Most cases have occurred in the United Kingdom, raising concerns about potential asymptomatic carriers within the population.
Until recently, all confirmed vCJD cases involved individuals with a specific genetic makeup (methionine homozygous) at codon 129 of the prion protein gene. However, the emergence of a patient with a different genetic variation (methionine/valine heterozygous) in 2016 raised concerns about a possible 'second wave' of vCJD, as this patient's symptoms mimicked those of sporadic CJD (sCJD), making diagnosis challenging.
To address this diagnostic challenge, researchers have developed a highly sensitive and specific test based on protein misfolding cyclic amplification (PMCA). This test can detect vCJD prions in cerebrospinal fluid (CSF), even in individuals with the methionine/valine heterozygous variation, allowing for accurate differentiation between vCJD and sCJD.
CJD, Prions, and Confirmation
Creutzfeldt-Jakob disease (CJD) is a rapidly progressive and always fatal neurodegenerative disorder believed to be caused by prions, which can trigger abnormal folding of normal brain proteins. Variant CJD (vCJD) is linked to eating beef from cows infected with mad cow disease; the CDC reports that vCJD illnesses have been very rare since the early 2000s and are usually fatal within 14 months of the first symptoms. A brain biopsy or examination of brain tissue after death (autopsy) is the gold standard for confirming CJD, although clinicians can often diagnose it before death using medical and personal history, neurological examination, and diagnostic tests.
Unlocking the PMCA Test: How It Works and What It Reveals
The newly developed test utilizes a technique called protein misfolding cyclic amplification (PMCA). PMCA works by amplifying misfolded prion proteins, which are the hallmark of vCJD. The test is performed on cerebrospinal fluid (CSF) samples, which are obtained through a spinal tap.
- Seeding: A small amount of the patient's CSF, potentially containing misfolded prions, is added to a solution containing normal prion proteins.
- Amplification: The mixture undergoes repeated cycles of incubation and sonication (ultrasound). The misfolded prions act as 'seeds', converting the normal prion proteins into the misfolded form.
- Detection: After several cycles, the amplified misfolded prions are detected using Western blotting, a technique that identifies specific proteins.
Emerging Diagnostic and Screening Approaches
A report on a heterozygous vCJD case notes that protein misfolding cyclic amplification (PMCA) in cerebrospinal fluid was positive in that case, but not in sporadic CJD (sCJD) cases, including cases with a heterozygous genotype. A separate diffusion-weighted imaging study reported that the pulvinar sign had 98% specificity for vCJD and was rare in sCJD. Researchers have also developed a highly sensitive protocol to analyze autopsy brain tissue for misfolded prion protein (PrPSc), with the potential to screen for prion disease in older people.
Promise and Limits of In-Life Diagnosis
In a reported methionine/valine variant CJD case, characteristic prion protein amplification in cerebrospinal fluid by protein misfolding cyclic amplification (PMCA) led to a specific diagnosis; the tested sCJD samples did not show positive results. This is evidence from a reported case and sample comparison, rather than a source establishing how reliably the approach performs across all patients. A 2025 article on difficulties in diagnosing CJD during life describes the disease as progressively degenerative, with varied neurological symptoms, steady progression, and inevitable death, underscoring the diagnostic challenge.
Clinical Differences Between sCJD and vCJD
Sporadic CJD typically affects people in their sixties and often presents with rapidly progressive dementia followed by focal neurological signs and myoclonus. By contrast, the CDC describes vCJD as typically beginning with psychiatric problems and causing death around 14 months later. The CDC also links vCJD to eating beef from cows infected with bovine spongiform encephalopathy (BSE); cases can only be confirmed by testing brain tissue, and there is no treatment for vCJD.
Why This Matters: Implications for Public Health and Future Research
The development of this highly specific PMCA test represents a significant advancement in the diagnosis and management of vCJD. It enables clinicians to accurately differentiate between vCJD and sCJD, even in patients with atypical genetic profiles, leading to earlier and more appropriate treatment.
Research Toward Future Treatments
A 2026 review describes CJD as a rare, still-fatal neurodegenerative disorder caused by prion protein misfolding in the central nervous system. It reports that accumulation of the pathogenic protein form leads to neuronal damage, spongiform degeneration, and rapidly progressive dementia. Another overview describes current care as focused on managing symptoms while researchers pursue future disease-modifying therapies; it does not identify a specific therapy or outcome.
Furthermore, the test has important implications for public health. By identifying individuals with vCJD, including those who may be asymptomatic carriers, it can help prevent further transmission of the disease through blood transfusions or surgical procedures.
Future research should focus on further refining the PMCA test and exploring its potential for diagnosing other prion diseases. The test could also be used to monitor the effectiveness of therapeutic interventions and to identify individuals at high risk of developing vCJD.